학술논문
Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease
Document Type
Article
Author
Wallentin, L.; Held, C.; Hagström, E.; Siegbahn, A.; Östlund, O.; Armstrong, P.W.; Cannon, C.P.; Davies, R.Y.; Krug-Gourley, S.; Tarka, E.; Granger, C.B.; Harrington, R.A.; Hochman, J.S.; Koenig, W.; Mohler, E.R.; Steg, P.G.; Stewart, R.A.H.; White, H.D.; Weiss, R.; Budaj, A.; Ardissino, D.; Avezum, A.; Aylward, P.E.; Bryce, A.; Chen, H.; Chen, M.-F.; Corbalan, R.; Dalby, A.J.; Danchin, N.; De Winter, R.J.; Denchev, S.; Diaz, R.; Elisaf, M.; Flather, M.D.; Goudev, A.R.; Grinfeld, L.; Husted, S.; Kim, H.-S.; Linhart, A.; Lonn, E.; López-Sendón, J.; Manolis, A.J.; Nicolau, J.C.; Pais, P.; Parkhomenko, A.; Pedersen, T.R.; Pella, D.; Ramos-Corrales, M.A.; Ruda, M.; Sereg, M.; Siddique, S.; Sinnaeve, P.; Sritara, P.; Swart, H.P.; Sy, R.G.; Teramoto, T.; Tse, H.-F.; Douglas Weaver, W.; Viigimaa, M.; Vinereanu, D.; Zhu, J.
Source
In: Journal of the American Heart Association . (Journal of the American Heart Association, 1 June 2016, 5(6))
Subject
Language
English
ISSN
20479980